Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)
NCT02704832
Adnexal Diseases, Bladder Cancer
Grenoble, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT Number: NCT01264744
The purpose of the study is the identification of chromosomal aberrations in urine samples.
The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classification of UroVysion FISH stained Urine samples.
Looking for future studies?
Notify MeAll sexes
Observational
VA Hospital, Los Angeles, California, United States
The FISH test detect chromosomal aberrations in urine specimens from persons with hematuria suspected of having bladder cancerous using the UroVysion® Bladder Cancer Kit (UroVysion Kit) which is FDA approved. This kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Looking for future studies?
Notify MeApplied Spectral Imaging Ltd.
Industry
Concordance Study for Detection of Chromosomal Aberrations Using FISH in Urine Samples Sections
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02704832
Adnexal Diseases, Bladder Cancer
Grenoble, Auvergne-Rhône-Alpes, France
View Trial DetailsNCT01352962
Adnexal Diseases, Bronchial Neoplasms
Bethesda, Maryland, United States
View Trial DetailsNCT05230186
Adenocarcinoma, Breast Diseases
Los Angeles, California, United States
View Trial DetailsNCT05858736
Adenocarcinoma, Adnexal Diseases
Darlinghurst, New South Wales, Australia
View Trial Details